NCT06611371View on ClinicalTrials.gov

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

August 26, 2025

Study Completion Date

February 28, 2026

Conditions
Group B Streptococcal Infections
Interventions
BIOLOGICAL

IVT GBS-06

Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.

BIOLOGICAL

Placebo

0.9% sodium chloride

Trial Locations (2)

10016

NYU Grossman School of Medicine, New York

Unknown

Wits Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), University of the Witwatersrand, Johannesburg

Sponsors

Lead Sponsor

Inventprise Inc.
All Listed Sponsors
collaborator

PATH

OTHER

lead

Inventprise Inc.

INDUSTRY

NCT06611371 - Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age. | Biotech Hunter | Biotech Hunter